RS-2024-00463231

Identification of a CDK7 inhibitor as a development candidate for HR+ HER2- metastatic breast cancer patients with resistance to CDK4/6 inhibitors

Cyrus Therapeutics

ONCOLOGY | **Candidate**

Product Type	Small Molecules
Indication	Solid Tumor
Target	CDK7
MoA(Mechanism of Action)	Inactivation of CDK7 by C-16661 induces cell cycle arrest and suppresses oncogene expression, resulting in potent tumor growth inhibition
Competitiveness	• C-16661 has excellent selectivity against other CDKs • C-16661 shows good physicochemical properties and ADME profiles • The PK profiles of C-16661 support a once-daily oral dosing schedule • C-16661 demonstrated potent in vivo antitumor activity with good tolerability • C-16661 exhibits a strong ability to modulate the PD markers in a time- and dose-dependent manner
Development Stage	Candidate
Route of Administration	Oral Administration

kddf_bd@kddf.org
KDDF Business Development Team

KDDF
Korea Drug Development Fund